🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

406 results for “The George Institute” Clear

  1. Bleomycin medac, 15 000 RÜ süstelahuse pulber

    The George Institute

    VASCULAR MALFORMATION

    phase 2 small molecule active

    1 trial

  2. Busulfan 6 mg/ml concentrate for solution for infusion, THYMOGLOBULINE 5 mg/ml, poudre pour solution pour perfusion, Fludarabine Accord Healthcare 25 mg/ml solution à diluer pour solution injectable /pour perfusion

    The George Institute

    High-risk myeloïd malignancies

    phase 2 small molecule active

    1 trial

  3. Byetta 10 micrograms solution for injection in pre-filled pen

    The George Institute

    Hypopituarism

    phase 2 small molecule active

    1 trial

  4. CABOMETYX 40 mg film-coated tablets, CABOMETYX 20 mg film-coated tablets, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    The George Institute

    Advanced /metastatic sarcomas: undifferentiated pleomorphic sarcoma, osteosarcoma and Ewing sarcoma.

    phase 2 small molecule active

    1 trial

  5. CAT-01

    The George Institute

    Cervical carcinoma

    phase 2 other active

    1 trial

  6. CIALIS 5 mg film-coated tablets

    The George Institute

    sexual/ erectile function in women and men after treatment for rectal cancer

    phase 2 small molecule active

    1 trial

  7. CISPLATIN, IMFINZI 50 mg/mL concentrate for solution for infusion., GEMCITABINE

    The George Institute

    Extrahepatic cholangiocarcinoma (eCCA)

    phase 2 small molecule active

    1 trial

  8. CISPLATINE VIATRIS 25 mg/25 ml, solution à diluer pour perfusion, Tecentriq 1 200 mg concentrate for solution for infusion, CARBOPLATINE ACCORD 10 mg/ml, solution pour perfusion, Paclitaxel Accord Healthcare 6 mg/ml solution à diluer pour perfusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, ALIMTA 500 mg powder for concentrate for solution for infusion, OPDIVO 10 mg/mL concentrate for solution for infusion.

    The George Institute

    Patients with locally advanced or metastasic Non-Small Cell Lung Carcinoma.

    phase 2 small molecule active

    1 trial

  9. CSG452 (Tofogliflozin) placebo, pemafibrate, K-877 ER (Pemafibrate) placebo, TOFOGLIFLOZIN

    The George Institute

    Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Liver Fibrosis

    phase 2 small molecule active

    1 trial

  10. CYCLOPHOSPHAMIDE, Paclitaxel 6 mg/mL concentrate for solution for infusion, Doxorubicin 2 mg/ml Concentrate for Solution for Infusion, DURVALUMAB, Oleclumab_IJB2

    The George Institute

    Luminal B Breast Cancer

    phase 2 small molecule active

    1 trial

  11. CYSTAGON 150 mg hard capsules

    The George Institute

    Infectious diseases of respiratory system (COVID-19)

    phase 2 small molecule active

    1 trial

  12. CYSTAGON 50 mg hard capsules

    The George Institute

    Pulmonary Tuberculosis

    phase 2 small molecule active

    1 trial

  13. Cannabidiol Capsules, Füllstoffmischung DAC in hardshell gelatine capsules, size 1, is used as placebo. Füllstoffmischung DAC consists of mannitol 99.5 % and silloidal silicon dioxide (Aerosil®) 0.5 %.

    The George Institute

    Remitted early phase schizophrenia

    phase 2 small molecule active

    1 trial

  14. Cannabidiol Placebo Capsules, Cannabidiol Capsules

    The George Institute

    Alcohol dependence

    phase 2 small molecule active

    1 trial

  15. Capecitabina KERN PHARMA 150 mg comprimidos recubiertos con película EFG, Oxaliplatin Hospira 5 mg/ml concentrate for solution for infusion, Oxaliplatin Hospira 5 mg/ml concentrate for solution for infusion, Fluorouracilo Accord 50 mg/ml solución inyectable o para perfusión EFG, Irinotecán Hospira 20 mg/mL concentrado para solución para perfusión EFG., Fluorouracilo Accord 50 mg/ml solución inyectable o para perfusión EFG, Fluorouracilo Accord 50 mg/ml solución inyectable o para perfusión EFG, Capecitabina

    The George Institute

    Localised Colon Cancer (stage II-III)

    phase 2 small molecule active

    1 trial

  16. Choice Of the Most Active Strategies for Short term recurring Triple Negative Breast Cancer A phase Ib/II, open-label, modular, dose-finding and dose-expansion study to explore safety, tolerability, pharmacokinetics, and anti-tumor activity of novel therapeutics in patients with early relapsed metastatic triple-negative breast cancer

    The George Institute

    Patients with hormone-receptor negative and HER2-negative (IHC 0, 1+ or IHC 2+/ISH-) breast cancer with early relapse while on (neo) adjuvant systemic treatment or within 12 months from the end of all treatments with curative intent.

    phase 2 other active

    1 trial

  17. Clinical Trial Using Humanized CART Directed Against BCMA (ARI0002h) in Patients With Relapsed/​Refractory Multiple Myeloma to Proteasome Inhibitors, Immunomodulators and Anti-CD38 Antibody

    The George Institute

    Multiple Myeloma

    phase 2 other active

    1 trial

  18. Columvi 10 mg concentrate for solution for infusion, Gazyvaro 1,000 mg concentrate for solution for infusion., Breyanzi 1.1-70 × 106 cells/mL / 1.1-70 × 106 cells/mL dispersion for infusion, YESCARTA 0.4 – 2 x 10e8 cells dispersion for infusion

    The George Institute

    relapsed/refractory Large B-Cell Lymphoma

    phase 2 small molecule active

    1 trial

  19. Curosurf, 240 mg/3 ml, suspensão para instilação endotraqueobrônquica

    The George Institute

    Premature infants with Respiratory Distress Syndrome (RDS)

    phase 2 small molecule active

    1 trial

  20. DASATINIB VIATRIS 50 mg, comprimé pelliculé, DASATINIB VIATRIS 70 mg, comprimé pelliculé

    The George Institute

    acute myeloid leukemia

    phase 2 small molecule active

    1 trial

  21. DASATINIB, Placebo

    The George Institute

    Asymptomatic patients with recent HIV-1 infection

    phase 2 small molecule active

    1 trial

  22. DOCETAXEL , AVELUMAB, FLUOROURACIL , OXALIPLATIN , CALCIUM FOLINATE

    The George Institute

    Resectable Gastric cancer (GC) or Gastroesophageal Junction cancer (GEJC)

    phase 2 small molecule active

    1 trial

  23. DOXORUBICINE ACCORD 2 mg/ml, solution pour perfusion, Bintrafusp alfa (anti-PD-L1/TGFβ Trap)

    The George Institute

    Adult patients with locally advanced/unresectable and/or metastatic soft-tissue sarcomas.

    phase 2 small molecule active

    1 trial

  24. Dasatinib/Teva 50 mg επικαλυμμένα με λεπτό υμένιο δισκία, Maltodextrine powder, SPRYCEL 20 mg film-coated tablets

    The George Institute

    Human immunodeficiency virus

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources